Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NYSE:BHVN NASDAQ:NMRA NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$21.68$21.17$7.80▼$24.25$1.42B-0.57495,263 shs365,781 shsBHVNBiohaven$9.45-0.1%$9.43$7.48▼$18.57$1.42B1.321.94 million shs1.44 million shsNMRANeumora Therapeutics$1.85$2.17$0.66▼$3.65$342.78M3.021.46 million shs1.36 million shsSLSSELLAS Life Sciences Group$7.78$5.33$1.39▼$9.10$1.45B2.248.68 million shs10.65 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics0.00%+12.39%-4.28%+33.50%+133.87%BHVNBiohaven0.00%+11.17%-4.25%-20.19%-39.72%NMRANeumora Therapeutics0.00%+4.52%-17.78%-46.06%+172.18%SLSSELLAS Life Sciences Group0.00%+6.72%+74.44%+64.14%+311.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$21.68$21.17$7.80▼$24.25$1.42B-0.57495,263 shs365,781 shsBHVNBiohaven$9.45-0.1%$9.43$7.48▼$18.57$1.42B1.321.94 million shs1.44 million shsNMRANeumora Therapeutics$1.85$2.17$0.66▼$3.65$342.78M3.021.46 million shs1.36 million shsSLSSELLAS Life Sciences Group$7.78$5.33$1.39▼$9.10$1.45B2.248.68 million shs10.65 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics0.00%+12.39%-4.28%+33.50%+133.87%BHVNBiohaven0.00%+11.17%-4.25%-20.19%-39.72%NMRANeumora Therapeutics0.00%+4.52%-17.78%-46.06%+172.18%SLSSELLAS Life Sciences Group0.00%+6.72%+74.44%+64.14%+311.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 2.71Moderate Buy$30.2739.63% UpsideBHVNBiohaven 2.71Moderate Buy$22.27135.75% UpsideNMRANeumora Therapeutics 2.56Moderate Buy$7.67314.41% UpsideSLSSELLAS Life Sciences Group 2.00Hold$10.0028.53% UpsideCurrent Analyst Ratings BreakdownLatest NMRA, BCAX, BHVN, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026BHVNBiohaven Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.005/12/2026BCAXBicara Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$36.00 ➝ $37.005/12/2026BCAXBicara Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$16.00 ➝ $18.005/11/2026BCAXBicara Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$42.005/10/2026BCAXBicara Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/5/2026BHVNBiohaven Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$23.00 ➝ $22.004/21/2026NMRANeumora Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SLSSELLAS Life Sciences Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/13/2026BHVNBiohaven Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.004/8/2026BCAXBicara Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/2/2026BHVNBiohaven CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$7.82 per shareN/ABHVNBiohavenN/AN/AN/AN/A$0.86 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$0.38 per shareN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$137.95M-$2.78N/AN/AN/AN/A-35.89%-33.78%8/11/2026 (Estimated)BHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)NMRANeumora Therapeutics-$236.93M-$1.33N/AN/AN/AN/A-181.70%-119.15%8/5/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest NMRA, BCAX, BHVN, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/11/2026Q1 2026BCAXBicara Therapeutics-$0.72-$0.93-$0.21-$0.93N/AN/A5/7/2026Q1 2026NMRANeumora Therapeutics-$0.32-$0.30+$0.02-$0.30N/AN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A3/30/2026Q4 2025BCAXBicara Therapeutics-$0.72-$0.68+$0.04-$0.68N/AN/A3/30/2026Q4 2025NMRANeumora Therapeutics-$0.34-$0.35-$0.01-$0.35N/AN/A3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/A3/2/2026Q4 2025BHVNBiohaven-$1.22-$1.21+$0.01-$1.21$3.86 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A13.8513.85BHVNBiohaven1.877.417.41NMRANeumora Therapeutics0.755.095.09SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ABHVNBiohaven88.78%NMRANeumora Therapeutics47.65%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipBCAXBicara Therapeutics15.50%BHVNBiohaven13.80%NMRANeumora Therapeutics26.94%SLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3265.70 million55.52 millionN/ABHVNBiohaven239150.56 million129.78 millionOptionableNMRANeumora Therapeutics108185.28 million135.37 millionOptionableSLSSELLAS Life Sciences Group10186.03 million183.43 millionNot OptionableNMRA, BCAX, BHVN, and SLS HeadlinesRecent News About These CompaniesSellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish SignalMay 22, 2026 | seekingalpha.comSLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomesMay 20, 2026 | msn.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSLS stock rallies after hours as CEO teases leukemia study data any day nowMay 19, 2026 | msn.comSELLAS Life Sciences (SLS) Is Up 50.5% After Pivotal AML Trial Nears Readout And Adds Funding Flexibility – Has The Bull Case Changed?May 16, 2026 | uk.finance.yahoo.comSLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readoutMay 14, 2026 | msn.comSELLAS Life Sciences to Participate in Upcoming Investor ConferencesMay 14, 2026 | globenewswire.comSLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readoutMay 13, 2026 | msn.comSELLAS rises as Q1 update suggests lead program nears final analysisMay 13, 2026 | seekingalpha.comSELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline ProgressesMay 13, 2026 | benzinga.comSELLAS Life Sciences surges on earnings beat, trial updateMay 12, 2026 | investing.comSELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 12, 2026 | globenewswire.comSLS stock heads for weekly win: Deutsche Bank’s stake boost draws attention ahead of Q1 earningsMay 8, 2026 | msn.comSELLAS Life Sciences Group (SLS) Expected to Announce Earnings on TuesdayMay 5, 2026 | marketbeat.comSLS stock kicks off week in green: CEO flags role in EU biotech policy talks that could impact drug approvalsMay 4, 2026 | msn.comSLS stock tests $5 again: Retail targets 'no' vote on 20M share dilution push before AML trial resultsMay 1, 2026 | msn.comSELLAS Life Sciences Group (SLS) price target increased by 15.38% to 10.20April 28, 2026 | msn.comSLS stock jumps overnight: CEO doubles down on ‘steadfast’ confidence in AML drug and pushes for 20M share plan approvalApril 27, 2026 | msn.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy?April 27, 2026 | marketbeat.comWhy SELLAS Life Sciences Group, Inc.’s (SLS) Stock Is Down 6.79%April 26, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeNMRA, BCAX, BHVN, and SLS Company DescriptionsBicara Therapeutics NASDAQ:BCAX$21.68 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$21.71 +0.03 (+0.14%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Biohaven NYSE:BHVN$9.44 -0.01 (-0.05%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$9.38 -0.06 (-0.69%) As of 05/22/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Neumora Therapeutics NASDAQ:NMRA$1.85 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.90 +0.05 (+2.97%) As of 05/22/2026 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.SELLAS Life Sciences Group NASDAQ:SLS$7.78 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.78 0.00 (0.00%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
